Cancer Center's lymphoma specialist, Dr. Palomba, provides an in-depth look at how CAR T-cell therapy is evolving to offer hope for more patients battling hematologic malignancies.

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

The Global Cancer Immunotherapy Market achieved a valuation of $121.2 Billion in 2023 and is anticipated to exceed $245.37 ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

A Scots schoolboy has 'rang the bell' to celebrate beating cancer after his symptoms were originally mistaken for norovirus.

China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...

Miss Charlesworth, who is leading the appeal to help find a match, said her father "means absolutely everything to me". The ...

Some New York doctors are working on new ways to treat advanced cancers. Chimeric Antigen Receptor, or CAR, T-cell therapy ...

Immunotherapy is leading the charge in the advancement of cancer treatment. In addition to increased life expectancy, it ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated ...

CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the m ...